Anebulo Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ANEB Nasdaq 2836 www.anebulo.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Anebulo Pharmaceuticals, Inc.

3 US Penny Stocks With Market Caps Under $800M - Dec 30th, 2024 8:04 pm
Anebulo Pharmaceuticals collaborates with FDA to advance selonabant - Dec 24th, 2024 2:25 pm
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise - Dec 23rd, 2024 2:15 pm
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates - Nov 13th, 2024 9:05 pm
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates - Sep 25th, 2024 8:05 pm
Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation - Sep 22nd, 2024 12:03 pm
Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects - Jul 22nd, 2024 11:00 am
Lifecore Biomedical Announces Cooperation Agreement with 22NW - Jul 1st, 2024 12:00 pm
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates - May 15th, 2024 5:05 pm
We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Needs To Drive Business Growth Carefully - Apr 15th, 2024 10:03 am
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates - Feb 13th, 2024 9:05 pm